These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 27053677)

  • 1. In Vitro Comparison of Ertapenem, Meropenem, and Imipenem against Isolates of Rapidly Growing Mycobacteria and Nocardia by Use of Broth Microdilution and Etest.
    Brown-Elliott BA; Killingley J; Vasireddy S; Bridge L; Wallace RJ
    J Clin Microbiol; 2016 Jun; 54(6):1586-1592. PubMed ID: 27053677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
    Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
    Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro activity of new carbapenem antibiotics: comparative studies with meropenem, L-627 and imipenem against pathogenic Nocardia spp.
    Yazawa K; Mikami Y; Ohashi S; Miyaji M; Ichihara Y; Nishimura C
    J Antimicrob Chemother; 1992 Feb; 29(2):169-72. PubMed ID: 1506332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug sensitivity analysis of Mycobacterium chelonae and Mycobacterium abscessus and evaluation of Etest for susceptibility testing].
    Gui J; Wang F; Hong CY; Li JL; Liang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Aug; 36(8):567-71. PubMed ID: 24252731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
    Joly-Guillou ML; Kempf M; Cavallo JD; Chomarat M; Dubreuil L; Maugein J; Muller-Serieys C; Roussel-Delvallez M
    BMC Infect Dis; 2010 Mar; 10():72. PubMed ID: 20298555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
    Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
    Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multisite reproducibility of Etest for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum.
    Woods GL; Bergmann JS; Witebsky FG; Fahle GA; Boulet B; Plaunt M; Brown BA; Wallace RJ; Wanger A
    J Clin Microbiol; 2000 Feb; 38(2):656-61. PubMed ID: 10655363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrepancies and interpretation problems in susceptibility testing of VIM-1-producing Klebsiella pneumoniae isolates.
    Giakkoupi P; Tzouvelekis LS; Daikos GL; Miriagou V; Petrikkos G; Legakis NJ; Vatopoulos AC
    J Clin Microbiol; 2005 Jan; 43(1):494-6. PubMed ID: 15635025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial susceptibility testing of rapidly growing mycobacteria isolated in Japan.
    Hatakeyama S; Ohama Y; Okazaki M; Nukui Y; Moriya K
    BMC Infect Dis; 2017 Mar; 17(1):197. PubMed ID: 28270102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
    Wexler HM; Engel AE; Glass D; Li C
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4413-7. PubMed ID: 16189137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum.
    Woods GL; Bergmann JS; Witebsky FG; Fahle GA; Wanger A; Boulet B; Plaunt M; Brown BA; Wallace RJ
    J Clin Microbiol; 1999 Jun; 37(6):1676-82. PubMed ID: 10325306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
    Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A
    Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro susceptibility of Haemophilus influenzae to meropenem compared with imipenem, five other beta-lactams, chloramphenicol and ciprofloxacin.
    Powell M; Seetulsingh P; Williams JD
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():175-81. PubMed ID: 2808206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various Nocardia species.
    Lai CC; Liu WL; Ko WC; Chen YH; Tan HR; Huang YT; Hsueh PR
    Antimicrob Agents Chemother; 2011 May; 55(5):2084-91. PubMed ID: 21343461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species.
    Lai CC; Tan CK; Lin SH; Liao CH; Chou CH; Hsu HL; Huang YT; Hsueh PR
    J Antimicrob Chemother; 2009 Jul; 64(1):73-8. PubMed ID: 19398458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro emergence of ertapenem resistance in Escherichia coli producing extended-spectrum β-lactamase].
    Villar HE; Jugo MB; Visser M; Hidalgo M; Hidalgo G; Maccallini GC
    Rev Esp Quimioter; 2014 Mar; 27(1):51-5. PubMed ID: 24676243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of cefoxitin and imipenem against Mycobacterium abscessus complex.
    Lavollay M; Dubée V; Heym B; Herrmann JL; Gaillard JL; Gutmann L; Arthur M; Mainardi JL
    Clin Microbiol Infect; 2014 May; 20(5):O297-300. PubMed ID: 24112243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variable performance of different commercial systems for testing carbapenem susceptibility of KPC carbapenemase-producing Escherichia coli.
    Antonelli A; Coppi M; Camarlinghi G; Parisio EM; Nardone M; Riccobono E; Giani T; Mattei R; Rossolini GM
    Clin Microbiol Infect; 2019 Nov; 25(11):1432.e1-1432.e4. PubMed ID: 31425743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of disk diffusion, Etest and VITEK2 for detection of carbapenemase-producing Klebsiella pneumoniae with the EUCAST and CLSI breakpoint systems.
    Vading M; Samuelsen Ø; Haldorsen B; Sundsfjord AS; Giske CG
    Clin Microbiol Infect; 2011 May; 17(5):668-74. PubMed ID: 20649801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.